Sign In
Buy RLFTF
$0.284
-0.0074 (-2.53%)
At Close: Jun 22, 2026
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
12:40pm, Friday, 14'th Nov 2025
Shareholders approve all EGM proposals related to the combination with NeuroX Business combination expected to close in December 2025 Relief to be renamed MindMaze Therapeutics Holding SA upon closing
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
02:20am, Wednesday, 29'th Oct 2025
RLF-OD032 demonstrated bioequivalence to KUVAN® Powder Study results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF THERAPEUT
Relief Therapeutics Publishes 2025 Half-Year Report
01:20am, Thursday, 14'th Aug 2025
GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering inno
Relief Therapeutics Advances Publication of 2025 Half-Year Report
01:20am, Monday, 11'th Aug 2025
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to deliver
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
01:20am, Tuesday, 29'th Jul 2025
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
01:20am, Friday, 20'th Jun 2025
GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics Announces Results of Annual General Meeting
06:17am, Thursday, 12'th Jun 2025
Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics,
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
01:20am, Thursday, 22'nd May 2025
GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
01:20am, Thursday, 15'th May 2025
GENEVA, SWITZERLAND / ACCESS Newswire / May 15, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative trea
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
01:20am, Thursday, 10'th Apr 2025
GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative tr
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
01:15am, Thursday, 06'th Mar 2025
GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innov
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
01:20am, Tuesday, 11'th Feb 2025
Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTC
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
01:20am, Wednesday, 22'nd Jan 2025
Sale of GOLIKE® Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / REL
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
01:20am, Friday, 27'th Dec 2024
GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to deliverin
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
01:20am, Monday, 16'th Dec 2024
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU Patients Results Expected to Promote Awareness and Adoption of PKU GOLIKE ® GENEVA, SWITZERLAND / ACCESSWIRE / D
